ArabFinance:  GlaxoSmithKline (GSK Egypt) (BIOC) is committed to collaborating with the governments worldwide to provide Sotrovimab, a drug used as a treatment for Covid-19, to deal with the pandemic, GSK said in a statement filed to the Egyptian Exchange (EGX).

Sotrovimab is only available in a few countries, the company noted.

This came after the US Drug and Food Authority allowed the urgent use of Sotrovimab in treating low-to-medium symptoms of Covid-19.

The recently published news regarding the drug has no impact on the EGX-listed GSK Egypt.

It is worth noting that Sotrovimab has been developed by the UK’s GlaxoSmithKine Plc, in cooperation with the US’ Vir.

GSK Egypt, a member of the British pharmaceutical company Glaxo Group, is an Egypt-based company engaged in the manufacture, packaging, marketing, sale, and distribution of pharmaceutical products.